1 / 44

BIOTERRORISM

BIOTERRORISM. Dr. E. McNamara Public Health Lab. HSE, Dublin. St. James’s Hospital. ‘9/11 – Changes’. Move to high risk Biological Threat, specialist public arena Newsworthy Rare/eradicated infections Low clinical experience. ‘Autumn 2001 – USA’. 5 letters, finely milled anthrax spores

malise
Download Presentation

BIOTERRORISM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BIOTERRORISM Dr. E. McNamara Public Health Lab. HSE, Dublin. St. James’s Hospital.

  2. ‘9/11 – Changes’ • Move to high risk • Biological Threat, specialist public arena • Newsworthy • Rare/eradicated infections • Low clinical experience

  3. ‘Autumn 2001 – USA’ • 5 letters, finely milled anthrax spores • 11 pulmonary anthrax (5 died) • 7 cutaneous anthrax • All sent from Trenton, New Jersey, 1 person • American origin, B. anthracis • Criminal Act : Terrorist

  4. ‘Lessons Learned’ • No one prepared • Easy to produce contagious material • Easy to spread, (except aerosolization) • Small numbers affected, major concern • Copy cat phenomenon – ‘Hoaxes’ • Lab. techniques for diagnosis • Major disruption • Use of prophylactic antibiotics

  5. Benefits • Co-operation internationally • WHO • CDC • EU • National preparedness Plans • Multidisciplinary • Government • Admininstrative • Emergency services • Medical • Scientific

  6. History – Biological Warfare • Water wells contaminated with corpses • Siege Caffa, Crimea 1346, used plague corpses • British, gave Smallpox contaminated blankets as presents to Native Americans

  7. Modern History – Biological Warfare • Germany WWI • sold anthrax infected horses • WWI-II • Many countries started biological programme • WWII – Not Used • UK 5 million anthrax ‘cattle-cakes’ • USA Botulinum • Canada Plague • Germany Salmonella • Japan POW/Chinese trials

  8. Post WWII • USA • 3400 people 1969, BTWC • Allegation • Korean War • Cuba • Misinformation, FBI to Soviets • Soviets • 1920 – 1969, BTWC signed • 1975 Enlarged, Biopreparat 60,000 people 40-50 facilities 50 agents

  9. Post WWII contd. • 1979 Sverdlovks, Anthrax, 69 died • 1980 – 1990 Defections • 1990 Yelsin – cessation? • Iraq 1974?, S. Africa 1980-1993 • 10 – 12 trying to acquire, evidence?

  10. Preparing for Biological Attacks • Enhance surveillance • Resource laboratories • Communication systems • Bioterrorism education • Stockpile vaccines and drugs • Molecular surveillance microbial strains • Support development diagnostic tests • Support research Rx. and vaccines CDC April 2000

  11. Biological Agents • Category A • Easily dessiminated • High mortality • Public panic • Require special preparedness • Category B • Moderately easy to dessiminate • Low mortality • Need enhanced Dx./surveillance • Category C • Emerging pathogens

  12. Anthrax, B. anthracis • Zoonotic, spore forming rod • Soil reservoir, years • Affects large domestic and wild herbivoires • Worldwide • Humans • Contact with infected animals/products • Skin – cutaneous • GIT/resp. – inhalation • 2000 cases, cutaneous / year • 5 cases USA, 1 case UK • No cases Ireland for 25 years

  13. Anthrax contd. • Bioterrorist threat – inhalation spores • No person – person spread ! (cutaneous?) • Cutaneous • Skin inoculation • Painless swelling • Papular – vescle – ulcer • Black eschar • Toxaemia • Mortality with Rx., < 1%. • GIT • Ingest contaminated meat • Pain, diarrhoea, haematemesis, septicaemia • Mortality > 50%

  14. Anthraxcontd. • Dx. (Confirm reference laboratory) • Hazard Group 3 – CL3 • Non motile, GPB, Aerobic • Central / Terminal spores • Non–haemolytic • Sensitivity tests • Rx. – Penicillin / Ciprofloxacin • Post exposure prophylaxis = Ciprofloxacin • Infection Contol – standard precautions

  15. Biological Agents • Category A • Easily dessiminated • High mortality • Public panic • Require special preparedness • Category B • Moderately easy to dessiminate • Low mortality • Need enhanced Dx./surveillance • Category C • Emerging pathogens

  16. Anthrax, B. anthracis • Zoonotic, spore forming rod • Soil reservoir, years • Affects large domestic and wild herbivoires • Worldwide • Humans • Contact with infected animals/products • Skin – cutaneous • GIT/resp. – inhalation • 2000 cases, cutaneous / year • 5 cases USA, 1 case UK • No cases Ireland for 25 years

  17. Anthrax contd. • Bioterrorist threat – inhalation spores • No person – person spread ! (cutaneous?) • Cutaneous • Skin inoculation • Painless swelling • Papular – vescle – ulcer • Black eschar • Toxaemia • Mortality with Rx., < 1%. • GIT • Ingest contaminated meat • Pain, diarrhoea, haematemesis, septicaemia • Mortality > 50%

  18. Anthraxcontd. • Dx. (Confirm reference laboratory) • Hazard Group 3 – CL3 • Non motile, GPB, Aerobic • Central / Terminal spores • Non–haemolytic • Sensitivity tests • Rx. – Penicillin / Ciprofloxacin • Post exposure prophylaxis = Ciprofloxacin • Infection Contol – standard precautions

  19. Inhalation Anthrax • Bioterrorist agent • Mortality 90% • Incubation 1 – 60 days • Initial Phase (hrs – days) • Non-specific symptoms • Non-specific clincial signs + Dx. test • Recover / Progress to fulminant • Fulminant Phase • Septicaemia / Toxaemia • Dyspnoea with CXR mediastenal widening • 50% haemorrhagic menigitis and death • Mortality increased with short incubation

  20. Deleted picture

  21. Small Pox • Human, DNA variola virus • 2 Forms • Variola major, mortality 30% (3% vaccinated) • Variola minor, mortality 1% • Airborne spread, contact • Secondary attack rate 50% (unvaccinated) • Last death – 1978 UK. • WHO 1980, eradicated.

  22. Small Pox contd. • Incubation 12-14 days, rash further 2-4 days • Fever, headache, myalgia, abdominal pain and vomiting • Delirium 15% • Rash, centrifugal, face and extremities • Copious virus on mucosal lesions • Secondary bacterial pneumonia (mortality > 50%) • Haemorrhagic Small Pox (95% mortality) • Differental = Chicken Pox.

  23. Small Pox contd. • Dx. • Hazard Group 4 • EM (Herpes : Pox) - CL3 • PCR (differentites Pox viruses) – CL4 • Culture – CL4 • Public Health Emergency – International • Case: Standard, contact and airborne precautions • Isolate: negative pressure, HEPA extract • PPE. Decontamination protocol • Immune HCW (vaccinated) • Rx. = supportive • Contact/Exposed • Quarantine for 18 days - monitor temperature • Infectious form onset of fever

  24. Small Pox Vaccine • Face – face contacts • HCW (core, prepardness) • Designated emergency personnel • Vaccine • Live vaccinia virus (not variola) • Vaccine site, infectious until scab heals • Newer vaccine development • S/E • Efficancy

  25. Small Pox Vaccine contd. • CI – atopic dermatitis, pregnant, immunocompromised • S/E • Fever headache, rigors, vastles • Generalised vaccinia (GV) • Eczema vaccinatum (EV) • Progressive vaccinia (PV) • Post vaccinial CNS (PVE) • Incident 1968 • Life threatening = 52 / million • Deaths = 1.5 / million

  26. Deleted picture

  27. Deleted picture

  28. Deleted picture

  29. Cl. Botulinum • Botulinum neurotoxin – most potent • Contaminated food, canned products • Wound botulism, contaminated soil, IVDA • Bioterrorism agent • Aerosolisation – inhalation • Contaminate food – ingestion • Large numbers with acute flaccid paralysis

  30. Cl. Botulinum contd. • Incubation • 2hrs – 8 days, Foodborne • 1hr – 5 days, Aerosol • Foodborne • V+D, diplopia, dysarthria, weakness • Ptosis, facial palsy, ↓gag Hypotonic • Inhalation • Dysplagia, nystagmins, ↓speech, ↓gait • Terminal • Progressive muscular paralysis • Mortality 5% (with Rx.)

  31. Cl. Botulinum contd. • Differential Dx. • Guillain-Barré • Myastheria gravis • Stoke • CNS despressants

  32. Cl. Botulinum contd. • Dx.: • Detect botulinum toxin • Culture • Rx.: • Antitoxin • Supportive • Infection Control – standard precautions

  33. Deleted picture

  34. Deleted picture

  35. Plague • Yersinia pestis – HG3 • GNCB, 02 • Aerosol, flea vector, person-person • 3 Forms • Bubonic – 90% • Septicaemic – 10% • Pneumonic – 1% • Bioterrorist agent • Aerosol – pneumonic • Fleas – bubonic, septicaemic

  36. Bubonic Plague • Incubation 1-8 days • Fever, rigors, headache • Buboes – painful lymph nodes • 15% develop pneumonic plague • Mortality = 12%

  37. Septicaemic Plague • Primary, or secondary to bubonic • Rigors, abdominal pain, V+D • Purpura, DIC, necrosis • Mortality = 30%

  38. Pneumonic Plague • Highest bioterrorism risk • Primary or secondary from haematogenous • Incubation 1-3 days • Pneumonic symptoms • Respiratory failure and shock • Mortality - ↓with rx. = 8%

  39. Plague • Dx.: • Culture • Rx.: • Gentamicin, Streptomycin IV • Ciprofloxacin, Doxycycline P.O. • Infection Control: • Standard and droplet, single room, surgical mask • Contacts: • Prophylaxis – Ciprofloxacin – 72 hrs.

  40. Deleted picture

  41. Deleted picture

  42. Tularaemia • F. tularensis • Non-motile, aerobic, GNCB, zoonosis, rabbits, deerfly • HG3 • Worldwide • Low inoculum – 10 CFU • Ulceroglandular • Typhoidal • Mortality 35-60% (untreated) • Inhalation • Infection Control – standard (no person-person) • Rx. Gentamicin/Streptomycin – 10 days • Contacts : prophylaxis

  43. Deleted picture Tularaemia

  44. Deleted picture Tularaemia

More Related